Evidence map›Paper›PMID 26752215›Full record

ArticleBiochemistry2016

Visualizing the Mechanism of Epoxide Hydrolysis by the Bacterial Virulence Enzyme Cif.

Christopher D Bahl, Kelli L Hvorecny, Christophe Morisseau, Scott A Gerber, Dean R Madden

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Christopher D Bahl
Kelli L Hvorecny
Christophe MorisseauDepartment of Entomology and Nematology, UCD Comprehensive Cancer Center, University of California at Davis , One Shields Ave., Davis, California 95616, United States.
Scott A Gerber
Dean R Madden
Dartmouth College · USUniversity of California, Davis · US

Funding

Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1987 to 2021
$50.1M
Molecular and Cellular Biology at DartmouthT32GM008704 · NIGMS · DARTMOUTH COLLEGE · PI COMPTON, DUANE A. · 1998 to 2018
$6.8M
TRANSLATIONAL RESEARCH COREP30GM106394 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2013 to 2017
$6.1M
HOST-MICROBE INTERACTIONST32AI007519 · NIAID · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 1997 to 2026
$5.9M
HYDROLYTIC ENZYMES IN THE METABOLISM OF TOXINSR01ES002710 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI HAMMOCK, BRUCE D · 1985 to 2018
$4.0M
RENAL FUNCTION AND DISEASET32DK007301 · NIDDK · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 1986 to 2014
$2.3M
Mechanism of Cif Virulence: A Bacterial Strategy to Subvert Host-Cell DefensesR01AI091699 · NIAID · DARTMOUTH COLLEGE · PI MADDEN, DEAN R, O'TOOLE, GEORGE A. · 2012 to 2016
$2.3M
Translational phosphoproteomics for lung cancerR01CA155260 · NCI · DARTMOUTH COLLEGE · PI GERBER, SCOTT A. · 2011 to 2015
$1.8M
NCI NIH HHS R01 CA155260NCI NIH HHS R01-CA155260NIAID NIH HHS R01 AI091699NIAID NIH HHS R01-AI091699NIAID NIH HHS T32 AI007519NIAID NIH HHS T32-AI007519NIDDK NIH HHS T32 DK007301NIDDK NIH HHS T32-DK007301NIEHS NIH HHS P42 ES004699NIEHS NIH HHS P42-ES004699NIEHS NIH HHS R01 ES002710NIEHS NIH HHS R01-ES002710NIGMS NIH HHS P30 GM106394NIGMS NIH HHS P30-GM106394NIGMS NIH HHS T32 GM008704NIGMS NIH HHS T32-GM008704
6 · The paper itself

Abstract

The CFTR inhibitory factor (Cif) is an epoxide hydrolase (EH) virulence factor secreted by the bacterium Pseudomonas aeruginosa. Sequence alignments reveal a pattern of Cif-like substitutions that proved to be characteristic of a new subfamily of bacterial EHs. At the same time, crystallographic and mutagenetic data suggest that EH activity is required for virulence and that Cif's active site remains generally compatible with a canonical two-step EH mechanism. A hallmark of this mechanism is the formation of a covalent hydroxyalkyl-enzyme intermediate by nucleophilic attack. In several well-studied EHs, this intermediate has been captured at near stoichiometric levels, presumably reflecting rate-limiting hydrolysis. Here we show by mass spectrometry that only minimal levels of the expected intermediate can be trapped with WT Cif. In contrast, substantial amounts of intermediate are recovered from an active-site mutant (Cif-E153Q) that selectively targets the second, hydrolytic release step. Utilizing Cif-E153Q and a previously reported nucleophile mutant (Cif-D129S), we then captured Cif in the substrate-bound, hydroxyalkyl-intermediate, and product-bound states for 1,2-epoxyhexane, yielding the first crystallographic snapshots of an EH at these key stages along the reaction coordinate. Taken together, our data illuminate the proposed two-step hydrolytic mechanism of a new class of bacterial virulence factor. They also suggest that the failure of WT Cif to accumulate a covalent hydroxyalkyl-enzyme intermediate reflects an active-site chemistry in which hydrolysis is no longer the rate-limiting step, a noncanonical kinetic regime that may explain similar observations with a number of other EHs.

Indexed as

Bacterial ProteinsCatalysisCrystallography, X-RayEpoxy CompoundsHydrolysisModels, MolecularProtein ConformationPseudomonas aeruginosaVirulence FactorsBacterial ProteinsCif protein, Pseudomonas aeruginosaEpoxy CompoundsVirulence Factors

Identifiers

PMID26752215
PMCPMC4765904
OpenAlexW2237056219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.